Study purposes and objectives have shifted

This is a feasibility, prospective, single center, open label, uncontrolled clinical study, to evaluate the safety and preliminary efficacy of the different R&D changes made and implemented in the existing PillCam Capsule products family, PillCam Endoscopy System subunits, the Patency system and bowel preparation procedure.

The study consists of a screening - enrollment phase, a possible preparation phase followed by the PillCam Endoscopy or Patency procedure visit and a post procedure telephone, follow up visit.

Subjects may be assigned to any of the sub-assays done within this study as long as they fulfill all the inclusion and exclusion criteria and depends on their availability and their willingness to participate in a specific sub-assay.

Each subject may participate in up to 15 sub-assays during his/her participation in the study, each ingestion will be separated in between by at least two weeks interval. A following capsule may be ingested only upon verification of previous capsule excretion. Subjects can participate in a specific sub-assay only once.

In general, under the study protocol, per a single procedure, each subject will undergo a possible preparation phase followed by the PillCam endoscopy or Patency procedure and telephone follow up visit. Overall the expected duration for subject's participation in the study is expected to be up to 10 years, until subject will complete participation in up to 15 sub-assays.

Subject may withdraw consent at any time and will be considered as completed once completed at least one capsule ingestion (PillCam or Patency) or completed one of the possible procedures which are not involving capsule ingestion during the study period.

Inclusion Criteria:

1. Subject either male or female is 45-85 years of age.
2. The subject is in good general health to enable participation in the study.
3. The subject received an explanation and understands the nature of the study and agrees to provide written informed consent.

Exclusion Criteria:

1. Subject has dysphagia or any swallowing disorder.
2. Subject is known or is suspected to suffer from intestinal obstruction or stricture (symptoms such as severe abdominal pain with accompanying nausea or vomiting).
3. Subject with known gastrointestinal motility disorders.
4. Subjects with known or suspected delayed gastric emptying.
5. Subject has known or suspected Crohn's disease, other inflammatory bowel disease, perforations or structural disorders of the gut wall.
6. Subject has diabetes.
7. Subject has undergone certain prior abdominal surgery of the gastrointestinal tract, (other than uncomplicated appendectomy or uncomplicated cholecystectomy) which may interfere with the study, such as small bowel or colonic resection. This will be evaluated by the investigator.
8. Subject has any allergy or other contraindication to any materials including preparation used prior, during or after capsule endoscopy in the study.
9. Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
10. Subject has severe congestive heart failure or known renal or hepatic insufficiency.
11. Subject has a cardiac pacemakers or other implanted electromedical devices.
12. Subject has any condition, which according to the investigators judgment, precludes compliance with study and/or device instructions.
13. Females who are pregnant or nursing at the time of screening and/or during the study period, or are of child bearing potential without medically acceptable methods of contraception.
14. Subject is currently participating in another clinical study that may directly or indirectly affect the results of this study.
15. Subject is considered to be part of a vulnerable population (e.g. prisoners or those without sufficient mental capacity).